SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will webcast its Annual Meeting of Stockholders on Wednesday, May 23, 2007 at 10:00 a.m. Pacific Time from the company’s corporate headquarters in San Diego, CA. Following the Annual Meeting, Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The presentation will be webcast live, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin’s corporate website, located at www.amylin.com. To access the live webcast, please log on to Amylin’s site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,600 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of AmylinPharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com/
